Consensus Statement 2009 of the Austrian Diabetes Association: Oral Antidiabetics in the Treatment of Diabetes Mellitus Type 2

Treatment regimens of type-2 diabetes have changed significantly over the past years. Both, incretin mimetics as well as dipeptidyl-peptidase IV inhibitors, have been implemented into the therapy of diabetes. Risks and contraindications of glitazones have been discussed at length. New clinical trials investigating the safety and benefits of sulfonylureas especially on microvascular endpoints have been presented. Insulin-sensitizing metformin has been established as the first-line therapy for overweight or obese type-2 diabetics lacking contraindications or intolerance. Finally, benefits of intensive blood glucose lowering and control have been discussed intensively . This article summarizes the algorithms for the initiation and adjustment of therapy in type-2 diabetes as well as the benefits and contraindications of oral antidiabetics and incretin mimetics according to the recently published consensus statement of the Austrian Diabetes Association.